Corcept Q2 Revenue Jumps 32% to $256M, Raises 2026 Guidance to $1.1–$1.2B on Lifyorli Launch
CORT has more than doubled off its 52-week low of $28.66.
Summary
Corcept delivered a strong Q2 with revenue of $256.1M, up 32% year-over-year, driven by the launch of oncology drug Lifyorli which contributed $47.6M in its first quarter. The Cushing's syndrome franchise also hit record new prescriptions. Management raised full-year 2026 revenue guidance to $1.1–$1.2 billion, signaling confidence in sustained momentum. This follows a mixed Q1 where revenue missed estimates and the ALS trial failed, but the relacorilant NDA resubmission in June and DOJ declining to intervene in a qui tam suit have since shifted sentiment. The PDUFA date for relacorilant in Cushing's is December 17, 2026, with an EMA decision in ovarian cancer also expected this year. Multiple oncology and MASH trial readouts are due by year-end, providing a rich catalyst calendar.
At the time of this announcement, CORT was trading at $110.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10B. The 52-week trading range was $28.66 to $97.63. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.